Philippines To Demand Dengue Vaccine Refund From Sanofi Pasteur; Controversy Threatens Public’s Trust In Other Vaccines
Associated Press: Philippines wants money back from Sanofi for dengue vaccine
“The Philippine government will demand a refund of 3.5 billion pesos ($69.5 million) from vaccine maker Sanofi Pasteur and look at possible legal action after a study showed the vaccine used in a dengue immunization program could expose some people to severe illness, the health chief said Friday…” (Gomez, 12/8).
Reuters: Exclusive: Philippines defied experts’ advice in pursuing dengue immunization program
“As she announced in January 2016 that the Philippines would immunize one million children with a new dengue vaccine, the nation’s then health secretary Janette Garin boasted it was a world-first and a tribute to her country’s ‘expertise’ in research. … After Garin’s announcement, the Formulary Executive Council (FEC) of advisers urged caution over the vaccine because it said its safety and cost-effectiveness had not been established…” (Allard et al., 12/10).
Reuters: Philippines to seek refund of $59 million from Sanofi amid vaccine risk
“…The Philippines last week suspended a national immunization program after Sanofi’s recent findings that there was a risk of severe dengue occurring in previously uninfected people who were inoculated with Dengvaxia. Manila also halted sale of the vaccine in the country and has ordered a probe into the matter…” (Serapio, 12/8).
STAT: Sanofi scandal in the Philippines could spread dangerous mistrust of vaccines
“…Unfortunately, there are indications that the company, which could use a blockbuster product, should have taken its corporate foot off the gas pedal. And to restore confidence in vaccines, a reckoning is required…” (Silverman, 12/11).
The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.